Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, and the incidence of HCC continues to rise. Improved understanding of risk factors for HCC has allowed the development of more effective prevention and surveillance strategies to reduce the global burden of this malignancy. Because of the complex nature of HCC, arising in a background of chronic liver dysfunction and often associated with viral infection, appropriate treatment requires a multidisciplinary approach designed to control the cancer and treat the underlying liver disease. Treatment approaches vary based on disease stage and severity, making accurate diagnosis and staging of disease critical. This has been aided by the development of new staging criteria, such as the Barcelona Clinic Liver Cancer Staging System. For earlier-stage disease, resection, radiofrequency ablation, transplantation, and transarterial chemoembolization (TACE) are preferred treatment modalities that provide optimal outcome. Until recently, few treatment options existed for patients with more advanced disease. Improved understanding of the underlying biology of the disease and the development of molecularly targeted therapies, including the multitargeted angiokine dosorafenib, has improved outcomes in this patient population. Research into therapeutic targets and novel agents continues for more advanced disease.

Epidemiology and Risk Factors of HCC

Hepatocellular carcinoma is the third most common cause of cancer death worldwide, accounting for ~695,900 deaths yearly. Although the highest incidence of HCC is in Southeast and East Asia and sub-Saharan Africa, current epidemiologic trends show that the incidence of HCC in the United States is rising. Age-adjusted incidence rates from the Surveillance, Epidemiology, and End Results (SEER) registry show that the incidence of HCC has tripled between 1975 and 2005; the American Cancer Society estimated 28,720 new cases of HCC and 20,550 HCC-related deaths in the United States in 2012. The incidence and associated mortality of HCC varies based on ethnicity and age. Asians/Pacific Islanders show the highest incidence followed by Hispanics, Blacks, American Indians/Alaskan natives, and Whites. Among age groups, the highest increase in rates of HCC are found in men aged 50 to 59 years and 70 to 84 years.

Understanding the etiology and risk factors for HCC is important in appreciating global HCC trends and instituting appropriate prevention or screening approaches. Hepatitis B virus (HBV) is a well-known etiologic risk factor, and the high
incidence of HCC in China and Africa reflects the elevated prevalence of chronic HBV infection. However, HCC in the United States, Western Europe, and Japan more commonly arises in the context of liver injury due to chronic hepatitis C virus (HCV). Other important risk factors implicated in the etiology of HCC include aflatoxin B1 exposure, alcoholic cirrhosis, diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The risk of HCC was found to significantly increase with an alcohol exposure of > 80 g ethanol per day compared with no exposure, and was elevated 54-fold in the presence of both viral infection and alcohol exposure. Patients with diabetes had a significantly higher incidence rate (2.39 vs 0.87 per 10,000 person-years, respectively, \( p < 0.0001 \)) compared with patients without diabetes in a study of 824,263 patients. In a large prospective study, a high body mass index (BMI) of 35.0–39.9 was associated with a 4.5-fold increased risk of HCC. Moreover, synergistic interaction among alcohol exposure, diabetes, and obesity might further increase the risk of HCC. The relationship between tobacco use and risk of HCC is presently unclear; however, a case-controlled study demonstrated a fivefold increase in the risk of HCC after an exposure of 20 pack-years.

Given that chronic HBV and HCV infections are the major risk factors for HCC, prevention of these infections would have a huge impact on the worldwide incidence of HCC. Rigorous HBV vaccination measures have been highly successful in preventing both neonatally acquired HBV and adult HBV infections and consequently, in reducing the risk of HCC. In addition to vaccinations, some evidence indicates that antiviral therapies may play an important role in preventing complications from chronic HBV infection and progression to HCC. In a placebo-controlled study of 651 patients with chronic HBV infection, antiviral therapy with lamivudine reduced the incidence of HCC by 51% compared with placebo (3.9% vs 7.4%; hazard ratio [HR] = 0.49; \( p = 0.047 \)). In the case of HCV, where no vaccine is available, preventative strategies include disrupting transmission through good clinical practices, reducing high-risk behaviors through public education, and managing chronic infections with combined antiviral therapy including novel agents such as boceprevir or telaprevir. Other, modifiable risk factors, such as alcohol use, diabetes, obesity, and smoking, will likely get more attention once preventative strategies against viral hepatitis are well implemented.

Prior to discussing diagnostic and treatment approaches for HCC, the implications of the heterogeneity of HCC and underlying liver disease must be underscored. Although it is known that up to 70% of HCC develops in the setting of chronic liver disease, the molecular evolution of HCC is a complex, multistep process that is still not completely understood. However, two major mechanisms seem to be the most important: the development of liver cirrhosis and the alteration of oncogenes and tumor suppressor genes leading to aberrant cell signaling pathways. Targeting these signaling pathways represents a rationale for modern systemic therapy of HCC and is discussed later in this supplement.

Due to the complex nature of HCC and its association with liver dysfunction, the management of this malignancy requires close collaboration among a multidisciplinary team of hepatologists/gastroenterologists, pathologists, radiologists, surgeons, and oncologists. Timely selection of a therapeutic intervention and referral to the appropriate specialist within the multidisciplinary team is critical to deliver optimal patient care in this disease.

**Surveillance and Diagnosis**

Screening and surveillance are highly important for early detection of HCC in patients considered to be at risk, such as Asian HBV carriers, Blacks with hepatitis B, HBV carriers with family history of HCC, patients with cirrhosis and chronic HBV or HCV, genetic susceptibility (hemochromatosis, \( \alpha \)-antitrypsin deficiency), or cirrhosis of other etiology. Hepatologists/gastroenterologists at the forefront of managing patients with chronic liver diseases play a critical role in the implementation of surveillance programs. The combination of ultrasound and \( \alpha \)-fetoprotein (AFP) evaluation has been shown to reduce mortality by 37% in patients with HBV, supporting the need for HCC surveillance. However, in a pooled analysis in patients with early HCC, ultrasound was shown to have only 63% sensitivity. Cost-effectiveness and cost-benefit analyses have indicated that the surveillance strategy of ultrasound and AFP appears to be the best. A recent prospective study showed that ultrasound and AFP are complementary, with a sensitivity of 90% and specificity of 83%. The practice guidelines of the American Association for Liver Diseases (AASLD) recommend ultrasound alone at 6-month intervals for HCC surveillance, but the National Comprehensive Cancer Network (NCCN) and other societies recommend the combination of ultrasound and AFP. There is a need to identify novel biomarkers, either alone or to complement ultrasonography, to improve the performance characteristics for the detection of early HCC.

When suspicious nodules are identified, the current diagnostic algorithm (Fig. 1) proposed by the AASLD recommends that liver nodules < 1 cm be observed with ultrasound every 3 months until stability or growth of the lesion is established. For lesions > 1 cm, characteristic intense arterial uptake followed by contrast washout in the venous-delayed phases should be detected with 4-phase multidetector computer tomography (MDCT) or dynamic contrast-enhanced magnetic resonance imaging (MRI). With the improved accuracy and sensitivity of imaging modalities, liver biopsy is currently not indicated for the diagnosis of HCC in a cirrhotic liver, and is even considered controversial. Although specificity of liver biopsy is almost 100%, sensitivity varies and depends on the tumor size and location and the size of the needle used for biopsy. Additionally, there is a small risk (2.7%) of tumor seeding after liver biopsy. According to the AASLD guidelines, biopsy is warranted only in instances where neither MDCT nor MRI shows characteristics of HCC, and is most useful in hypovascular tumors and in small nodules < 1 cm. Histologic confirmation of HCC requires positive results for at least two of the following three immunostains: glypican 3, heat shock protein 70, and glutamine synthetase.
Staging and Outcome of HCC

Prognosis and treatment options for HCC are dependent not only on the tumor stage, but also on the magnitude of liver impairment; therefore, conventional staging systems used in the majority of other cancers, such as the tumor-node-metastasis (TNM) staging system, are insufficient. Several HCC staging systems incorporating liver function, such as the Okuda classification,\(^{26}\) Cancer of the Liver Italian Program (CLIP),\(^{27,28}\) Chinese University Prognostic Index (CUPI),\(^{29}\) and Japanese Integrated System (JIS),\(^{30}\) have been developed; however, they do not adequately stratify patients across the continuum of HCC and fail to provide treatment guidance or prognostic accuracy.\(^{31,32}\) In contrast, the Barcelona Clinic Liver Cancer (BCLC) Staging System (Fig. 2) stratifies patients based on tumor stage, performance status, cancer-related symptoms, and liver function status as assessed by the Child-Pugh score to provide specific treatment recommendations that can be correlated with life expectancy.\(^{33–36}\) The Child-Pugh score uses five clinical measures of liver function (total bilirubin, serum albumin, ascites, hepatic encephalopathy, and prothrombin international normalized ratio [PT INR]) to categorize patients into Child-Pugh class A–C, which correlate with the severity of liver disease.\(^{36}\) The BCLC Staging System is currently a preferred staging system for HCC, and is endorsed by both the American and European Medical Associations.\(^{17,37–39}\)

According to BCLC staging, very early-stage HCC includes patients with solitary, vaguely nodular tumors < 2 cm, preserved liver function (Child-Pugh A), and no vascular or distant metastasis. Although these patients have the best prognosis, very early-stage HCC is difficult to diagnose. Early-stage disease includes patients with either solitary tumors < 5 cm or up to three nodules < 3 cm in size, no vascular invasion or extrahepatic dissemination (constituting the Milan criteria for liver transplantation), and Child-Pugh A or B liver function. Several curative treatment modalities are applicable in this patient subset, yielding a 5-year survival of 50–75%. The intermediate stage includes patients with large multinodular tumors beyond the Milan criteria, Child-Pugh A or B liver disease, and no vascular invasion or extrahepatic spread; these patients have an average predicted 3-year survival of ~29% with current therapies. Advanced stage includes patients with Eastern Cooperative Group Performance Status (ECOG PS) 1 or 2 with tumors that may be accompanied by vascular invasion or extrahepatic spread;

![Fig. 1 Algorithm for diagnosis of hepatocellular carcinoma (HCC): American Association for Liver Diseases guidelines.\(^{17}\) US, Ultrasound; MRI, magnetic resonance imaging; CT, computed tomography; MDCT, 4-phase multidetector computer tomography. (Reprinted with permission from Bruix J, et al. Hepatology 2011; 53(3):1020–1022. Copyright John Wiley and Sons.)](image1)

![Fig. 2 Barcelona Clinic Liver Cancer Staging System for hepatocellular carcinoma (HCC).\(^{17}\) RFA, Radiofrequency ablation; TACE, transarterial chemoembolization. (Reprinted with permission from Bruix J, et al. Hepatology 2011; 53(3):1020–1022. Copyright John Wiley and Sons.)](image2)
1-year survival rate is ~ 50%. End-stage disease includes patients exhibiting cancer symptoms and decompensated liver function (Child–Pugh C); the median survival of this patient subset is < 3 months.33

**Current Treatment Modalities for HCC**

The treatment strategy for a patient with HCC is selected based on cancer stage, patient performance status, and underlying liver disease, and includes radical surgery (resection or transplantation), locoregional therapy (radiofrequency ablation [RFA], transarterial chemoembolization [TACE], or embolization), systemic therapy (sorafenib), or a combination of these strategies.

**Early-Stage HCC**

Treatment options for patients with early-stage HCC are largely dictated by the severity of liver dysfunction, portal hypertension (defined as a hepatic venous pressure gradient > 10 mm Hg), and presence of comorbidities. Surgical resection is the standard of care for patients with very early-stage or early-stage HCC with well-preserved liver function (no cirrhosis or Child-Pugh A), normal bilirubin (< 1 mg/dL), and no portal hypertension.17 In patients with portal hypertension and elevated bilirubin (≥ 1 mg/dL), a high risk of irreversible postoperative clinical decompensation and a reduced survival of 25% have been observed that preclude the use of surgical resection in this subset of patients.40 Unfortunately, early-phase and late-phase intrahepatic recurrences have been reported after surgical resection, with 5-year recurrence rates exceeding 70%.41–43 Although predictors of recurrence have not been completely defined, there is some evidence to suggest that microvascular invasion and serum AFP > 32 ng/mL might be strong predictive factors for postoperative early recurrence (< 2 years), although grade of hepatitis activity, tumor nodule multiplicity, and gross tumor classification may predict late recurrence (≥ 2 years).42–46 Some evidence indicates that adjuvant therapy with interferon may reduce the risk of recurrence; however, further validation is required before its role can be established in this setting.47,48 Salvage transplantation may be indicated for selected previously resected patients such as those with recurrences due to de novo oncogenesis or those who show pathological evidence of vascular invasion prior to proven recurrence.49,50

Liver transplantation offers the best survival benefit for patients with early-stage disease by reducing the potential for recurrence through the elimination of undetectable liver lesions and underlying liver disease. The above-mentioned Milan criteria are globally used to select patients for liver transplantation; patients receiving a transplant according to this criteria have a 4-year overall survival (OS) of 75% and only an 8% risk of recurrence.51 To expand listing criteria for patients with HCC, the University of San Francisco (UCSF) developed modified criteria in which patients with a solitary lesion of ≤ 6.5 cm in diameter or ≤ 3 lesions ≤ 4.5 cm with a total combined diameter of ≤ 8 cm are eligible for transplant.52 However, the UCSF criteria have not been formally adopted by United Network for Organ Sharing (UNOS) due to the scarcity of donor livers. The UNOS primarily uses the Model for End-Stage Liver Disease (MELD) criteria, a composite score of liver function parameters that assesses the risk of life-threatening liver failure, to allocate available livers for transplantation. Because MELD does not consider mortality risk from HCC, additional points are given for presence of HCC to prioritize for transplantation. The long waiting time between listing and transplantation has also led to strategies for increasing the donor pool, such as using living donors and split liver transplantation.17,53 In addition, withdrawal from the waiting list due to disease progression might be reduced by use of a locoregional “bridge therapy,” such as TACE or ablation.54–57 There is evidence that response to preoperative TACE to “downstage” HCC led to better long-term survival following transplantation, particularly in patients that fit the Milan criteria.58,59 Importantly, the number of donors available for liver transplant has plateaued over the past 10 years to ~ 1500/year for patients with HCC,60 while the number of patients with HCC has grown significantly to over 28,000.4 Therefore, liver transplantation as a treatment for HCC is limited in its scope.

For patients who are unsuitable for surgical resection or liver transplantation, locoregional therapy using image-guided percutaneous tumor ablation methods is the treatment of choice. RFA has demonstrated a superior survival benefit compared with percutaneous ethanol injection in patients with early-stage HCC, particularly those with compensated liver disease (Child-Pugh A).61 Radiofrequency ablation was associated with a 5-year OS of 76% when used as frontline therapy in patients with resectable HCC by BCLC criteria, which is comparable to the survival rates achieved historically with surgical resection.52,63 Two prospective randomized trials demonstrated that RFA was as effective as surgical resection in terms of OS or recurrence-free survival while being less invasive and having fewer complications.64,65 These results question the use of surgical resection as standard first-line therapy in all patients with very early-stage HCC, and support consideration of RFA in this setting. However, RFA has several limitations and showed suboptimal results in patients with tumor size ≥ 3 cm and perivascularly located tumors.66 To overcome these limitations, numerous refinements of ablation methods are under clinical testing, including laser ablation, microwave ablation, cryoablation light-activated therapy, and irreversible electroporation.

**Intermediate-Stage HCC**

Patients with large multimodal tumors, preserved liver function, and no vascular invasion or extrahepatic spread who are ineligible for radical surgical therapies or percutaneous ablation are usually treated with TACE.17 Transarterial chemoembolization involves the intra-arterial injection of a cytotoxic agent (doxorubicin, cisplatin, or mitomycin), with or without lipiodol, plus an embolic agent into the hepatic artery that supplies the tumor. In a meta-analysis of seven studies, TACE demonstrated a significant improvement in 2-year survival (odds ratio = 0.53; p = 0.017) compared with best supportive care.67 However, patient selection appears to...
be critical for achieving a survival advantage with this method. In the positive Barcelona study, a 2-year OS of 63% and objective responses of 35% were reported for patients treated with TACE, but 70% of them had compensated liver disease (Child-Pugh A) with no vascular invasion or extrahepatic spread. Another study found that among patients treated with TACE, those with unilobular portal vein invasion and tumors > 5 cm did not show a survival benefit.69 In both of these studies, the long-term outcomes were unsatisfactory with a 3-year OS of only ~30%, highlighting the need for improved strategies to optimize outcomes.

To further improve outcomes and tolerability of TACE, a new drug delivery system has been developed using doxorubicin-eluting beads (DEB), which provides embolization and releases the cytotoxic agent in a controlled fashion (DEB-TACE).70 Encouraging tolerability and response rates of 70–85% have been reported with this technique.71–74 However, in the recently reported, prospective, randomized phase II PRECISION V trial of 212 patients with intermediate-stage HCC, though DEB-TACE substantially reduced hepatic and doxorubicin-related systemic side effects compared with those found with conventional TACE, clear superiority in response rates was not demonstrated (52% vs 44%; p = 0.11).75 Clearly, further studies are warranted to define the role of DEB-TACE in HCC. In addition to TACE, radioembolization with yttrium-90 (90Y) microspheres represents a potential new treatment option for patients with Child-Pugh A cirrhosis and intermediate-stage HCC, but needs to be explored in randomized trials.76

Unresectable/Advanced-Stage HCC

Treatment options are limited for patients with unresectable advanced stage HCC or those for whom therapy with TACE has failed. Systemic chemotherapy, either single agent or in combination, demonstrated only minor antitumor activity (response rate < 30%) and failed to show an unequivocal improvement in OS.77–79 However, recent evidence that chemotherapy might have a role in HCC has emerged from an Asian phase III study where the FOLFOX4 (oxaliplatin/5-fluorouracil/leucovorin) chemotherapy regimen improved response rate, time to progression (TTP), and OS in patients with advanced stage HCC when compared with doxorubicin, but these results require further validation.80

Better understanding of the molecular pathogenesis of HCC has led to recognition of the importance of angiogenesis for tumor development, growth, and progression, thus making angiogenesis an attractive target. Proangiogenic factors, such as vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) and their receptors, have been shown to have important roles in facilitating HCC angiogenesis. Sorafenib, a multitargeted tyrosine kinase inhibitor that blocks several key modulators of angiogenesis, including VEGFR2, PDGFR, Raf-1 and B-Raf receptors, is the first drug to show a survival benefit in patients with advanced HCC and represents a paradigm shift in the systemic treatment of this disease. Its efficacy was proven in two large, randomized, placebo-controlled clinical trials, which mainly included patients with advanced HCC and Child-Pugh A liver disease.81,82 In the Sorafenib HCC Assessment Randomized Protocol (SHARP) study of 602 patients, most of whom were Caucasian, treatment with 400 mg sorafenib twice daily significantly prolonged TTP (5.5 months vs 2.8 months; HR = 0.58; 95% confidence interval [CI] 0.45–0.74; p < 0.001) and median OS (10.7 months vs 7.9 months, HR = 0.69; 95% CI 0.55–0.87; p < 0.001). In a similarly designed Asia-Pacific study of 271 Asian patients, sorafenib therapy prolonged TTP (2.8 months vs 1.4 months; HR = 0.57; 95% CI 0.42–0.72; p = 0.0005) and median OS (6.5 months vs 4.2 months; HR = 0.68; 95% CI 0.50–0.93; p = 0.014) compared with placebo. The inferior magnitude of benefit of the Asia-Pacific study compared with the SHARP study may be partly attributable to differences in patient characteristics, disease heterogeneity, and etiopathology between the trials. Seventy-five percent of patients in the Asia-Pacific study exhibited hepatitis B etiology, compared with only 19% in the SHARP study. In addition, patients enrolled in the Asia-Pacific study had a worse performance status and more advanced stage disease in general than those in the SHARP study. In both trials, hand-and-foot skin reaction, diarrhea, rash, and fatigue were among the most commonly reported adverse effects.

In both of these studies of sorafenib in the treatment of HCC, the improvements in OS and TTP were not accompanied by benefit in terms of objective response, highlighting the lack of utility of conventional RECIST criteria for evaluation of tumor response to molecular targeted therapy. Recently developed modified RECIST (mRECIST) criteria propose the assessment of response to molecular targeted therapy (or locoregional therapy) in patients with HCC based on measurement of viable tumor with arterial enhancement on a computed tomography scan, not anatomical tumor response.83 Although the mRECIST is utilized in the assessment of response in systemic therapies, it needs further validation. When response to sorafenib was assessed according to both mRECIST and conventional RECIST criteria in patients with advanced HCC, a higher rate of objective responses was identified with mRECIST (23% vs 2%), and patients who achieved a response according to mRECIST had a longer OS than nonresponding patients (18 months vs 8 months, p = 0.013).84

Although it is indisputable that sorafenib represents a major advancement in the management of unresectable advanced-stage HCC, several unanswered questions and unmet needs still remain. The clinical benefit with sorafenib appears to be modest and short-lived, even in patients with preserved liver function. In addition, there is currently no reliable predictive biomarker for monitoring response or indicating treatment resistance. The registrational trials also did not provide data on the safety and efficacy of sorafenib in patients with compromised liver function. However, the postapproval observational GIDEON study (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib) showed that sorafenib 400 mg twice daily could be safely prescribed to selected Child-Pugh B patients.85 Sorafenib is also being examined in the neoadjuvant and adjuvant settings in combination with locoregional therapies.
Conclusion

Recent years have witnessed significant changes in the management of HCC. Multidisciplinary approaches to management of this disease and diagnostic and treatment algorithms that accommodate the unique aspects of HCC, including its pathobiology, heterogeneity, and underlying liver impairment, have been developed. The introduction of sorafenib therapy has validated the targeted approach to this disease and represents a major paradigm shift in the treatment of advanced HCC, leading to the identification of other potential targets and the development of new targeted agents in HCC, which are discussed in the next article.

Acknowledgments

The author would like to thank Sabitha Muneer, PhD, Bojana Pajk, MD, MSc, Amy Furedy, RN, OCN, and Chelsey Goins, PhD, for their assistance in writing the manuscript, and Trudy Grenon Stoddert, ELS, for her editorial assistance and assistance preparing the manuscript for publication. Financial support was provided through an educational grant from Bristol-Myers Squibb Co.

References

9 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126(2):460–468


Chlebowski RT, Brzechwa-Adzukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984;68(3):487–491


